Skip to main content

Table 1 Clinical characteristics of subjects in this study

From: Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics

Group

N

Sex (M/F)

Age

Histology#

Discovery phase

 

Gliomas

5

2/3

45.20 ± 10.50

WHO-II (1); WHO-IV (4)

Validation phase

 

Gliomas

10

6/4

44.78 ± 12.20

WHO-II (2); WHO-III (2); WHO-IV(6)

Meningioma

5

2/3

54.60 ± 9.42

--

Moyamoya

6

3/3

37.67 ± 9.69

--

Healthy control

12

5/7

42.17 ± 8.42

--

  1. Glioma grade classified as World Health Organization (WHO) grades I–IV
  2. M male; F female